CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
25.16
+1.42 (5.98%)
At close: May 12, 2025, 4:00 PM
25.16
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
CG Oncology Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for CG Oncology stock have an average target of 62.9, with a low estimate of 41 and a high estimate of 75. The average target predicts an increase of 150.00% from the current stock price of 25.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 10 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $41 | Buy | Initiates | $41 | +62.96% | May 2, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $66 → $68 | Buy | Maintains | $66 → $68 | +170.27% | Apr 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $75 | Buy | Reiterates | $75 | +198.09% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +198.09% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +198.09% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
759.49K
from 1.14M
Decreased by -33.32%
Revenue Next Year
124.08M
from 759.49K
Increased by 16,237.24%
EPS This Year
-1.84
from -1.41
EPS Next Year
-1.58
from -1.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5M | 241.5M | 347.6M | ||
| Avg | 759,492 | 124.1M | 240.1M | ||
| Low | n/a | 49.0M | 104.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 121.2% | 31,702.8% | 180.1% | ||
| Avg | -33.3% | 16,237.2% | 93.5% | ||
| Low | - | 6,351.7% | -15.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.05 | -0.11 | 0.87 |
| Avg | -1.84 | -1.58 | -0.33 |
| Low | -2.39 | -3.49 | -1.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.